The ADAM10 Knockout Ca Ski Polyclonal Cells product delivers a population of Ca Ski cervical squamous carcinoma cells bearing CRISPR/Cas9-mediated disruption of the ADAM10 gene. As a polyclonal knockout pool, this model circumvents clonal selection biases and enables robust characterization of collective ADAM10-dependent functions. The abrogation of ADAM10, a principal ectodomain sheddase, provides a versatile loss-of-function system for dissecting metalloprotease-mediated signaling in epithelial tumor biology.
The Ca Ski host line was established from a metastatic cervical squamous cell carcinoma and harbors integrated HPV-16 genomes. These adherent epithelial cells constitutively express the viral E6 and E7 oncoproteins, which inactivate p53 and Rb, respectively, driving malignant transformation. Ca Ski cells thus serve as a widely used model for HPV-driven cervical carcinogenesis, recapitulating key aspects of viral oncogenesis, host?Cvirus interactions, and tumor progression.
ADAM10 is a transmembrane metalloprotease that cleaves the ectodomains of diverse substrates, including NOTCH1, E-cadherin, EGFR ligands, and TNF-??. In the Notch cascade, ADAM10-mediated S2 cleavage of NOTCH1 permits subsequent presenilin-dependent release of the Notch intracellular domain (NICD), which translocates to the nucleus, partners with RBPJ, and drives transcription of targets such as HES1. ADAM10 activity is modulated by upstream regulators like HPV-16 E6/E7, TspanC8 tetraspanins (Tspan14, Tspan15, Tspan33), protein kinase C, and intracellular calcium, and it interacts with integrin ??1 and chaperone proteins. By shedding E-cadherin, ADAM10 also influences epithelial adhesion and motility.
In Ca Ski cells, ADAM10 sits at a signaling junction where HPV E6/E7 dysregulation intersects with pathways controlling adhesion, migration, and proliferation. Disruption of ADAM10 expression cripples ligand-dependent Notch activation, stabilizes E-cadherin at the cell surface, and attenuates EGFR transactivation, thereby modulating invasive behavior. This knockout model thus offers a physiologically relevant platform to parse the contribution of ADAM10 to cervical cancer progression and to gauge the consequences of its proteolytic blockade in an HPV-positive epithelial context.
Investigators can employ this polyclonal knockout population to study ADAM10-dependent shedding in cervical carcinoma, map Notch signaling dynamics in HPV-driven tumors, screen for ADAM10 inhibitors, assess roles in EMT, and measure cell migration and invasion. Compatible experimental approaches include Western blotting for ADAM10 and its substrates, RT-qPCR, flow cytometry of surface NOTCH1, E-cadherin immunofluorescence, migration and invasion assays, Notch reporter luciferase systems, co-immunoprecipitation with tetraspanins, and phospho-EGFR analysis. For additional technical details, please contact Ascent Research.
